- Home
- APLT vs PRPO Comparison
APLT vs PRPO Comparison
Compare APLT & PRPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APLT | PRPO |
|---|---|---|
| Founded | 2016 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 38.1M | 32.4M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | APLT | PRPO |
|---|---|---|
| Price | $0.11 | $24.68 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $1.25 | N/A |
| AVG Volume (30 Days) | ★ 27.2M | 14.5K |
| Earning Date | 11-13-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,000,000.00 | ★ $22,800,000.00 |
| Revenue This Year | $124.18 | N/A |
| Revenue Next Year | $66.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 30.95 |
| 52 Week Low | $0.11 | $3.90 |
| 52 Week High | $1.50 | $28.50 |
Technical Indicators
Market Signals| Indicator | APLT | PRPO |
|---|---|---|
| Relative Strength Index (RSI) | 25.17 | 56.69 |
| Support Level | $0.21 | $23.92 |
| Resistance Level | $0.26 | $25.62 |
| Average True Range (ATR) | 0.02 | 1.34 |
| MACD | 0.01 | -0.09 |
| Stochastic Oscillator | 7.83 | 67.00 |
Price Performance
Historical ComparisonAbout APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About PRPO Precipio Inc.
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.